[1]
|
Anderson, W. (1898) A Case of “Angeio-Keratoma.” British Journal of Dermatology, 10, 113-117. https://doi.org/10.1111/j.1365-2133.1898.tb16317.x
|
[2]
|
Fabry, J. (1898) Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae). Archiv für Dermatologie und Syphilis, 43, 187-200. https://doi.org/10.1007/BF01986897
|
[3]
|
Brady, R.O., Gal, A.E., Bradley, R.M., Martensson, E., Warshaw, A.L. and Laster, L. (1967) Enzymatic Defect in Fabry’s Disease—Ceramidetrihexosidase Deficiency. The New England Journal of Medicine, 276, 1163-1167. https://doi.org/10.1056/NEJM196705252762101
|
[4]
|
Aerts, J.M., Groener, J.E., Kuiper, S., Donker-Koopman, W.E., Strijland, A., Ottenhoff, R., et al. (2008) Elevated Globotriaosylsphingosine Is a Hallmark of Fabry Disease. Proceedings of the National Academy of Sciences of the United States of America, 105, 2812-2817. https://doi.org/10.1073/pnas.0712309105
|
[5]
|
Kornreich, R., Desnick, R.J. and Bishop, D.F. (1989) Nucleotide Sequence of the Human α-Galactosidase a Gene. Nucleic Acids Research, 17, 3301-3302. https://doi.org/10.1093/nar/17.8.3301
|
[6]
|
Branton, M.H., Schiffmann, R., Sabnis, S.G., Murray, G.J., Quirk, J.M., Altarescu, G., et al. (2002) Natural History of Fabry Renal Disease: Influence of α-Galactosidase A Activity and Genetic Mutations on Clinical Course. Medicine, 81, 122-138. https://doi.org/10.1097/00005792-200203000-00003
|
[7]
|
Arends, M., Wanner, C., Hughes, D., Mehta, A., Oder, D., Watkinson, O.T., et al. (2017) Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study. Journal of the American Society of Nephrology, 28, 1631-1641. https://doi.org/10.1681/ASN.2016090964
|
[8]
|
Smid, B.E., Van der Tol, L., Biegstraaten, M., Linthorst, G.E., Hollak, C.E.M. and Poorthuis, B.J.H.M. (2015) Plasma Globotriaosylsphingosine in Relation to Phenotypes of Fabry Disease. Journal of Medical Genetics, 52, 262-268. https://doi.org/10.1136/jmedgenet-2014-102872
|
[9]
|
MacDermot, K.D., Holmes, A. and Miners, A.H. (2001) Anderson-Fabry Disease: Clinical Manifestations and Impact of Disease in a Cohort of 98 Hemizygous Males. Journal of Medical Genetics, 38, 750-760. https://doi.org/10.1136/jmg.38.11.750
|
[10]
|
Schiffmann, R., Warnock, D.G., Banikazemi, M., Bultas, J., Linthorst, G.E., Packman, S., et al. (2009) Fabry Disease: Progression of Nephropathy, and Prevalence of Cardiac and Cerebrovascular Events before Enzyme Replacement Therapy. Nephrology Dialysis Transplantation, 24, 2102-2111. https://doi.org/10.1093/ndt/gfp031
|
[11]
|
Desnick, R.J., Ioannou, Y.A. and Eng, C.M. (2019) α-Galactosidase A Deficiency: Fabry Disease. In: Valle, D.L., Antonarakis, S., Ballabio, A., Beaudet, A.L. and Mitchell, G.A., Eds., The Online Metabolic and Molecular Bases of Inherited Disease, McGraw-Hill Education, New York. https://ommbid.mhmedical.com/content.aspx?bookid=2709§ionid=225546984
|
[12]
|
MacDermot, K.D., Holmes, A. and Miners, A.H. (2001) Anderson-Fabry Disease: Clinical Manifestations and Impact of Disease in a Cohort of 60 Obligate Carrier Females. Journal of Medical Genetics, 38, 769-775. https://doi.org/10.1136/jmg.38.11.769
|
[13]
|
Mehta, A., Ricci, R., Widmer, U., Dehout, F., Garcia De Lorenzo, A., Kampmann, C., et al. (2004) Fabry Disease Defined: Baseline Clinical Manifestations of 366 Patients in the Fabry Outcome Survey. European Journal of Clinical Investigation, 34, 236-242. https://doi.org/10.1111/j.1365-2362.2004.01309.x
|
[14]
|
Echevarria, L., Benistan, K., Toussaint, A., Dubourg, O., Hagege, A.A., Eladari, D., et al. (2016) X-Chromosome Inactivation in Female Patients with Fabry Disease. Clinical Genetics, 89, 44-54. https://doi.org/10.1111/cge.12613
|
[15]
|
Rodríguez-Marí, A., Coll, M.J. and Chabás, A. (2003) Molecular Analysis in Fabry Disease in Spain: Fifteen Novel GLA Mutations and Identification of a Homozygous Female. Human Mutation, 22, 258. https://doi.org/10.1002/humu.9172
|
[16]
|
Ferreira, S., Ortiz, A., Germain, D.P., Viana-Baptista, M., Caldeira-Gomes, A., Camprecios, M., et al. (2015) The α-Galactosidase A p.Arg118Cys Variant Does Not Cause a Fabry Disease Phenotype: Data from Individual Patients and Family Studies. Molecular Genetics and Metabolism, 114, 248-258. https://doi.org/10.1016/j.ymgme.2014.11.004
|
[17]
|
Oder, D., Vergho, D., Ertl, G., Wanner, C. and Nordbeck, P. (2016) Case Report of a 45-Year Old Female Fabry Disease Patient Carrying Two α-Galactosidase A Gene Mutation Alleles. BMC Medical Genetics, 17, Article No. 46. https://doi.org/10.1186/s12881-016-0309-z
|
[18]
|
Meikle, P.J., Hopwood, J.J., Clague, A.E. and Carey, W.F. (1999) Prevalence of Lysosomal Storage Disorders. JAMA, 281, 249-254. https://doi.org/10.1001/jama.281.3.249
|
[19]
|
Thadhani, R., Wolf, M., West, M.L., Tonelli, M., Ruthazer, R., Pastores, G.M., et al. (2002) Patients with Fabry Disease on Dialysis in the United States. Kidney International, 61, 249-255. https://doi.org/10.1046/j.1523-1755.2002.00097.x
|
[20]
|
Van Der Tol, L., Smid, B.E., Poorthuis, B.J.H.M., Biegstraaten, M., Deprez, R.H.L., Linthorst, G.E., et al. (2014) A Systematic Review on Screening for Fabry Disease: Prevalence of Individuals with Genetic Variants of Unknown Significance. Journal of Medical Genetics, 51, 1-9. https://doi.org/10.1136/jmedgenet-2013-101857
|
[21]
|
Eng, C.M., Guffon, N., Wilcox, W.R., Germain, D.P., Lee, P., Waldek, S., et al. (2001) Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry’s Disease. The New England Journal of Medicine, 345, 9-16. https://doi.org/10.1056/NEJM200107053450102
|
[22]
|
Schiffmann, R., Kopp, J.B., Austin III, H.A., Sabnis, S., Moore, D.F., Weibel, T., et al. (2001) Enzyme Replacement Therapy in Fabry Disease. JAMA, 285, 2743-2749. https://doi.org/10.1001/jama.285.21.2743
|
[23]
|
Germain, D.P., Hughes, D.A., Nicholls, K., Bichet, D.G., Giugliani, R., Wilcox, W.R., et al. (2016) Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat. The New England Journal of Medicine, 375, 545-555.
|
[24]
|
Terré, A., Knebelmann, B., Buob, D., Rabant, M., Lidove, O., Deshayes, S., et al. (2020) AA Amyloidosis Associated with Fabry Disease. International Journal of Clinical Practice, 74, e13577. https://doi.org/10.1111/ijcp.13577
|
[25]
|
Galafold (2023) GLA Mutation Search. https://www.galafoldamenabilitytable.com/
|
[26]
|
Tsakiris, D., Simpson, H.K.L., Jones, E.H.P., Briggs, J.D., Elinder, C.G., Mendel, S., et al. (1996) Rare Diseases in Renal Replacement Therapy in the ERA-EDTA Registry. Nephrology Dialysis Transplantation, 11, 4-20. https://doi.org/10.1093/ndt/11.supp7.4
|
[27]
|
Laney, D.A., Peck, D.S., Atherton, A.M., Manwaring, L.P., Christensen, K.M., Shankar, S.P., et al. (2015) Fabry Disease in Infancy and Early Childhood: A Systematic Literature Review. Genetics in Medicine, 17, 323-330. https://doi.org/10.1038/gim.2014.120
|
[28]
|
Najafian, B., Svarstad, E., Bostad, L., Gubler, M.C., T&slash;ndel, C., Whitley, C., et al. (2011) Podocyte Injury and GL-3 Accumulation Are Progressive in Young Patients with Fabry Disease. Kidney International, 79, 663-670. https://doi.org/10.1038/ki.2010.484
|
[29]
|
T&slash;ndel, C., Kanai, T., Larsen, K.K., Ito, S., Politei, J.M., Warnock, D.G., et al. (2015) Foot Process Effacement Is an Early Marker of Nephropathy in Young Classic Fabry Patients without Albuminuria. Nephron, 129, 16-21. https://doi.org/10.1159/000369309
|
[30]
|
Vujkovac, B., Kirbiš, I.S., Keber, T., Vujkovac, A.C., Tretjak, M. and Krnel, S.R. (2022) Podocyturia in Fabry Disease: A 10-Year Follow-up. Clinical Kidney Journal, 15, 269-277. https://doi.org/10.1093/ckj/sfab172
|
[31]
|
Najafian, B., T&slash;ndel, C., Svarstad, E., Gubler, M.C., Oliveira, J.P. and Mauer, M. (2020) Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss. Journal of the American Society of Nephrology, 31, 865-875. https://doi.org/10.1681/ASN.2019050497
|
[32]
|
Mauer, M., Glynn, E., Svarstad, E., T&slash;ndel, C., Gubler, M.C., West, M., et al. (2014) Mosaicism of Podocyte Involvement Is Related to Podocyte Injury in Females with Fabry Disease. PLOS ONE, 9, e112188. https://doi.org/10.1371/journal.pone.0112188
|
[33]
|
Becker, G.J. and Nicholls, K. (2015) Lipiduria—With Special Relevance to Fabry Disease. Clinical Chemistry and Laboratory Medicine, 53, S1465-S1470. https://doi.org/10.1515/cclm-2015-0499
|
[34]
|
Najafian, B., Fogo, A.B., Lusco, M.A. and Alpers, C.E. (2015) AJKD Atlas of Renal Pathology: Fabry Nephropathy. American Journal of Kidney Diseases, 66, E35-E36. https://doi.org/10.1053/j.ajkd.2015.08.006
|
[35]
|
Braun, F., Abed, A., Sellung, D., Rogg, M., Woidy, M., Eikrem, O., et al. (2023) Accumulation of α-Synuclein Mediates Podocyte Injury in Fabry Nephropathy. Journal of Clinical Investigation, 133, e157782. https://doi.org/10.1172/JCI157782
|
[36]
|
Ortiz, A., Germain, D.P., Desnick, R.J., Politei, J., Mauer, M., Burlina, A., et al. (2018) Fabry Disease Revisited: Management and Treatment Recommendations for Adult Patients. Molecular Genetics and Metabolism, 123, 416-427. https://doi.org/10.1016/j.ymgme.2018.02.014
|
[37]
|
Germain, D.P., Fouilhoux, A., Decramer, S., Tardieu, M., Pillet, P., Fila, M., et al. (2019) Consensus Recommendations for Diagnosis, Management and Treatment of Fabry Disease in Paediatric Patients. Clinical Genetics, 96, 107-117. https://doi.org/10.1111/cge.13546
|
[38]
|
Terryn, W., Cochat, P., Froissart, R., Ortiz, A., Pirson, Y., Poppe, B., et al. (2013) Fabry Nephropathy: Indications for Screening and Guidance for Diagnosis and Treatment by the European Renal Best Practice. Nephrology Dialysis Transplantation, 28, 505-517. https://doi.org/10.1093/ndt/gfs526
|
[39]
|
Schiffmann, R., Hughes, D.A., Linthorst, G.E., Ortiz, A., Svarstad, E., Warnock, D.G., et al. (2017) Screening, Diagnosis, and Management of Patients with Fabry Disease: Conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney International, 91, 284-293. https://doi.org/10.1016/j.kint.2016.10.004
|
[40]
|
Ortiz, A., Oliveira, J.P., Waldek, S., Warnock, D.G., Cianciaruso, B. and Wanner, C. (2008) Nephropathy in Males and Females with Fabry Disease: Cross-Sectional Description of Patients before Treatment with Enzyme Replacement Therapy. Nephrology Dialysis Transplantation, 23, 1600-1607. https://doi.org/10.1093/ndt/gfm848
|
[41]
|
Weidemann, F., Sanchez-Niño, M.D., Politei, J., Oliveira, J.P., Wanner, C., Warnock, D.G., et al. (2013) Fibrosis: A Key Feature of Fabry Disease with Potential Therapeutic Implications. Orphanet Journal of Rare Diseases, 8, Article No. 116. https://doi.org/10.1186/1750-1172-8-116
|
[42]
|
Warnock, D.G., Thomas, C.P., Vujkovac, B., Campbell, R.C., Charrow, J., Laney, D.A., et al. (2015) Antiproteinuric Therapy and Fabry Nephropathy: Factors Associated with Preserved Kidney Function during Agalsidase-β Therapy. Journal of Medical Genetics, 52, 860-866. https://doi.org/10.1136/jmedgenet-2015-103471
|
[43]
|
Waldek, S. and Feriozzi, S. (2014) Fabry Nephropathy: A Review—How Can We Optimize the Management of Fabry Nephropathy? BMC Nephrology, 15, Article No. 72. https://doi.org/10.1186/1471-2369-15-72
|
[44]
|
Liern, M., Collazo, A., Valencia, M., Fainboin, A., Isse, L., Costales-Collaguazo, C., et al. (2019) Podocyturia in Pediatric Patients with Fabry Disease. Nefrologia, 39, 177-183. https://doi.org/10.1016/j.nefroe.2019.03.001
|
[45]
|
Fall, B., Scott, C.R., Mauer, M., Shankland, S., Pippin, J., Jefferson, J.A., et al. (2016) Urinary Podocyte Loss Is Increased in Patients with Fabry Disease and Correlates with Clinical Severity of Fabry Nephropathy. PLOS ONE, 11, e0168346. https://doi.org/10.1371/journal.pone.0168346
|
[46]
|
Selvarajah, M., Nicholls, K., Hewitson, T.D. and Becker, G.J. (2011) Targeted Urine Microscopy in Anderson-Fabry Disease: A Cheap, Sensitive and Specific Diagnostic Technique. Nephrology Dialysis Transplantation, 26, 3195-3202. https://doi.org/10.1093/ndt/gfr084
|
[47]
|
Yonishi, H., Namba-Hamano, T., Hamano, T., Hotta, M., Nakamura, J., Sakai, S., et al. (2022) Urinary Mulberry Bodies as a Potential Biomarker for Early Diagnosis and Efficacy Assessment of Enzyme Replacement Therapy in Fabry Nephropathy. Nephrology Dialysis Transplantation, 37, 53-62. https://doi.org/10.1093/ndt/gfaa298
|
[48]
|
Ries, M., Bove Bettis, K.E., Choyke, P., Kopp, J.B., Austin, H.A., Brady, R.O., et al. (2004) Parapelvic Kidney Cysts: A Distinguishing Feature with High Prevalence in Fabry Disease. Kidney International, 66, 978-982. https://doi.org/10.1111/j.1523-1755.2004.00846.x
|
[49]
|
Van der Tol, L., Svarstad, E., Ortiz, A., T&slash;ndel, C., Oliveira, J.P., Vogt, L., et al. (2015) Chronic Kidney Disease and an Uncertain Diagnosis of Fabry Disease: Approach to a Correct Diagnosis. Molecular Genetics and Metabolism, 114, 242-247. https://doi.org/10.1016/j.ymgme.2014.08.007
|
[50]
|
Gal, A., Hughes, D.A. and Winchester, B. (2011) Toward a Consensus in the Laboratory Diagnostics of Fabry Disease—Recommendations of a European Expert Group. Journal of Inherited Metabolic Disease, 34, 509-514. https://doi.org/10.1007/s10545-010-9261-9
|
[51]
|
Linthorst, G.E., Vedder, A.C., Aerts, J.M.F.G. and Hollak, C.E.M. (2005) Screening for Fabry Disease Using Whole Blood Spots Fails to Identify One-Third of Female Carriers. Clinica Chimica Acta, 353, 201-203. https://doi.org/10.1016/j.cccn.2004.10.019
|
[52]
|
Deegan, P.B., Baehner, A.F., Barba Romero, M.A., Hughes, D.A., Kampmann, C. and Beck, M. (2006) Natural History of Fabry Disease in Females in the Fabry Outcome Survey. Journal of Medical Genetics, 43, 347-352. https://doi.org/10.1136/jmg.2005.036327
|
[53]
|
Schiffmann, R., Waldek, S., Benigni, A. and Auray-Blais, C. (2010) Biomarkers of Fabry Disease Nephropathy. Clinical Journal of the American Society of Nephrology, 5, 360-364. https://doi.org/10.2215/CJN.06090809
|
[54]
|
Schiffmann, R., Forni, S., Swift, C., Brignol, N., Wu, X., Lockhart, D.J., et al. (2014) Risk of Death in Heart Disease Is Associated with Elevated Urinary Globotriaosylceramide. Journal of the American Heart Association, 3, e000394. https://doi.org/10.1161/JAHA.113.000394
|
[55]
|
Kim, J.Y., Hyun, Y.Y., Lee, J.E., Yoon, H.R., Kim, G.H., Yoo, H.W., et al. (2010) Serum Globotriaosylceramide Assay as a screening Test for Fabry Disease in Patients with ESRD on Maintenance Dialysis in Korea. The Korean Journal of Internal Medicine, 25, 415-421. https://doi.org/10.3904/kjim.2010.25.4.415
|
[56]
|
Pastores, G.M. and Hughes, D.A. (2009) To See a World in a Grain of Sand: Elucidating the Pathophysiology of Anderson-Fabry Disease through Investigations of a Cellular Model. Kidney International, 75, 351-353. https://doi.org/10.1038/ki.2008.606
|
[57]
|
Maruyama, H., Miyata, K., Mikame, M., Taguchi, A., Guili, C., Shimura, M., et al. (2019) Effectiveness of Plasma Lyso-Gb3 as a Biomarker for Selecting High-Risk Patients with Fabry Disease from Multispecialty Clinics for Genetic Analysis. Genetics in Medicine, 21, 44-52. https://doi.org/10.1038/gim.2018.31
|
[58]
|
Togawa, T., Kodama, T., Suzuki, T., Sugawara, K., Tsukimura, T., Ohashi, T., et al. (2010) Plasma Globotriaosylsphingosine as a Biomarker of Fabry Disease. Molecular Genetics and Metabolism, 100, 257-261. https://doi.org/10.1016/j.ymgme.2010.03.020
|
[59]
|
Van der Veen, S.J., el Sayed, M., Hollak, C.E.M., Brands, M.M., Snelder, C.K.S., Boekholdt, S.M., et al. (2023) Early Risk Stratification for Natural Disease Course in Fabry Patients Using Plasma Globotriaosylsphingosine Levels. Clinical Journal of the American Society of Nephrology, 18, 1272-1282. https://doi.org/10.2215/CJN.0000000000000239
|
[60]
|
Smid, B.E., Van der Tol, L., Cecchi, F., Elliott, P.M., Hughes, D.A., Linthorst, G.E., et al. (2014) Uncertain Diagnosis of Fabry Disease: Consensus Recommendation on Diagnosis in Adults with Left Ventricular Hypertrophy and Genetic Variants of Unknown Significance. International Journal of Cardiology, 177, 400-408. https://doi.org/10.1016/j.ijcard.2014.09.001
|
[61]
|
Fogo, A.B., Bostad, L., Svarstad, E., Cook, W.J., Moll, S., Barbey, F., et al. (2010) Scoring System for Renal Pathology in Fabry Disease: Report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrology Dialysis Transplantation, 25, 2168-2177. https://doi.org/10.1093/ndt/gfp528
|
[62]
|
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., et al. (2015) Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine, 17, 405-424. https://doi.org/10.1038/gim.2015.30
|
[63]
|
Lenders, M. and Brand, E. (2018) Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease. Journal of the American Society of Nephrology, 29, 2265-2278. https://doi.org/10.1681/ASN.2018030329
|
[64]
|
Lenders, M., Pollmann, S., Terlinden, M. and Brand, E. (2022) Pre-Existing Anti-Drug Antibodies in Fabry Disease Show Less Affinity for Pegunigalsidase Alfa. Methods & Clinical Development, 26, 323-330. https://doi.org/10.1016/j.omtm.2022.07.009
|
[65]
|
Hughes, D.A., Bichet, D.G., Giugliani, R., Hopkin, R.J., Krusinska, E., Nicholls, K., et al. (2022) Long-Term Multisystemic Efficacy of Migalastat on Fabry-Associated Clinical Events, Including Renal, Cardiac and Cerebrovascular Outcomes. Journal of Medical Genetics, 60, 722–731. https://doi.org/10.1136/jmg-2022-108669
|
[66]
|
Wanner, C., Oliveira, J.P., Ortiz, A., Mauer, M., Germain, D.P., Linthorst, G.E., et al. (2010) Prognostic Indicators of Renal Disease Progression in Adults with Fabry Disease: Natural History Data from the Fabry Registry. Clinical Journal of the American Society of Nephrology, 5, 2220-2228. https://doi.org/10.2215/CJN.04340510
|
[67]
|
Thurberg, B.L., Rennke, H., Colvin, R.B., Dikman, S., Gordon, R.E., Collins, A.B., et al. (2002) Globotriaosylceramide Accumulation in the Fabry Kidney Is Cleared from Multiple Cell Types after Enzyme Replacement Therapy. Kidney International, 62, 1933-1946. https://doi.org/10.1046/j.1523-1755.2002.00675.x
|
[68]
|
Mauer, M., Sokolovskiy, A., Barth, J.A., Castelli, J.P., Williams, H.N., Benjamin, E.R., et al. (2017) Reduction of Podocyte Globotriaosylceramide Content in Adult Male Patients with Fabry Disease with Amenable GLA Mutations following 6 Months of Migalastat Treatment. Journal of Medical Genetics, 54, 781-786. https://doi.org/10.1136/jmedgenet-2017-104826
|
[69]
|
Schwarting, A., Dehout, F., Feriozzi, S., Beck, M., Mehta, A., Sunder-Plassmann, G., et al. (2006) Enzyme Replacement Therapy and Renal Function in 201 Patients with Fabry Disease. Clinical Nephrology, 66, 77-84.
|
[70]
|
Feriozzi, S., Schwarting, A., Sunder-Plassmann, G., West, M. and Cybulla, M. (2009) Agalsidase Alfa Slows the Decline in Renal Function in Patients with Fabry Disease. American Journal of Nephrology, 29, 353-361. https://doi.org/10.1159/000168482
|
[71]
|
Mehta, A., Beck, M., Elliott, P., Giugliani, R., Linhart, A., Sunder-Plassmann, G., et al. (2009) Enzyme Replacement Therapy with Agalsidase Alfa in Patients with Fabry’s Disease: An Analysis of Registry Data. The Lancet, 374, 1986-1996. https://doi.org/10.1016/S0140-6736(09)61493-8
|
[72]
|
Beck, M., Hughes, D., Kampmann, C., Larroque, S., Mehta, A., Pintos-Morell, G., et al. (2015) Long-Term Effectiveness of Agalsidase Alfa Enzyme Replacement in Fabry Disease: A Fabry Outcome Survey Analysis. Molecular Genetics and Metabolism Reports, 3, 21-27. https://doi.org/10.1016/j.ymgmr.2015.02.002
|
[73]
|
Germain, D.P., Elliott, P.M., Falissard, B., Fomin, V.V., Hilz, M.J., Jovanovic, A., et al. (2019) The Effect of Enzyme Replacement Therapy on Clinical Outcomes in Male Patients with Fabry Disease: A Systematic Literature Review by a European Panel of Experts. Molecular Genetics and Metabolism Reports, 19, Article ID: 100454. https://doi.org/10.1016/j.ymgmr.2019.100454
|
[74]
|
Germain, D.P., Arad, M., Burlina, A., Elliott, P.M., Falissard, B., Feldt-Rasmussen, U., et al. (2019) The Effect of Enzyme Replacement Therapy on Clinical Outcomes in Female Patients with Fabry Disease—A Systematic Literature Review by a European Panel of Experts. Molecular Genetics and Metabolism, 126, 224-235. https://doi.org/10.1016/j.ymgme.2018.09.007
|
[75]
|
Spada, M., Baron, R., Elliott, P.M., Falissard, B., Hilz, M.J., Monserrat, L., et al. (2019) The Effect of Enzyme Replacement Therapy on Clinical Outcomes in Paediatric Patients with Fabry Disease—A Systematic Literature Review by a European Panel of Experts. Molecular Genetics and Metabolism, 126, 212-223. https://doi.org/10.1016/j.ymgme.2018.04.007
|
[76]
|
Van der Veen, S.J., Körver, S., Hirsch, A., Hollak, C.E.M., Wijburg, F.A., Brands, M.M., et al. (2022) Early Start of Enzyme Replacement Therapy in Pediatric Male Patients with Classical Fabry Disease Is Associated with Attenuated Disease Progression. Molecular Genetics and Metabolism, 135, 163-169. https://doi.org/10.1016/j.ymgme.2021.12.004
|
[77]
|
Rombach, S.M., Smid, B.E., Linthorst, G.E., Dijkgraaf, M.G.W. and Hollak, C.E.M. (2014) Natural Course of Fabry Disease and the Effectiveness of Enzyme Replacement Therapy: A Systematic Review and Meta-Analysis: Effectiveness of ERT in Different Disease Stages. Journal of Inherited Metabolic Disease, 37, 341-352. https://doi.org/10.1007/s10545-014-9677-8
|
[78]
|
El Dib, R., Gomaa, H., Ortiz, A., Politei, J., Kapoor, A. and Barreto, F. (2017) Enzyme Replacement Therapy for Anderson-Fabry Disease: A Complementary Overview of a Cochrane Publication through a Linear Regression and a Pooled Analysis of Proportions from Cohort Studies. PLOS ONE, 12, e0173358. https://doi.org/10.1371/journal.pone.0173358
|
[79]
|
Biegstraaten, M., Arngrímsson, R., Barbey, F., Boks, L., Cecchi, F., Deegan, P.B., et al. (2015) Recommendations for Initiation and Cessation of Enzyme Replacement Therapy in Patients with Fabry Disease: The European Fabry Working Group Consensus Document. Orphanet Journal of Rare Diseases, 10, Article No. 36. https://doi.org/10.1186/s13023-015-0253-6
|
[80]
|
Feldt-Rasmussen, U., Hughes, D., Sunder-Plassmann, G., Shankar, S., Nedd, K., Olivotto, I., et al. (2020) Long-Term Efficacy and Safety of Migalastat Treatment in Fabry Disease: 30-Month Results from the Open-Label Extension of the Randomized, Phase 3 ATTRACT Study. Molecular Genetics and Metabolism, 131, 219-228. https://doi.org/10.1016/j.ymgme.2020.07.007
|
[81]
|
Bichet, D.G., Torra, R., Wallace, E., Hughes, D., Giugliani, R., Skuban, N., et al. (2021) Long-Term Follow-up of Renal Function in Patients Treated with Migalastat for Fabry Disease. Molecular Genetics and Metabolism Reports, 28, Article ID: 100786. https://doi.org/10.1016/j.ymgmr.2021.100786
|
[82]
|
Müntze, J., Gensler, D., Maniuc, O., Liu, D., Cairns, T., Oder, D., et al. (2019) Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes after 1 Year. Clinical Pharmacology & Therapeutics, 105, 1224-1233. https://doi.org/10.1002/cpt.1321
|
[83]
|
Lenders, M., Nordbeck, P., Kurschat, C., Karabul, N., Kaufeld, J., Hennermann, J.B., et al. (2020) Treatment of Fabry’s Disease with Migalastat: Outcome from a Prospective Observational Multicenter Study (FAMOUS). Clinical Pharmacology & Therapeutics, 108, 326-337. https://doi.org/10.1002/cpt.1832
|
[84]
|
Tahir, H., Jackson, L.L. and Warnock, D.G. (2007) Antiproteinuric Therapy and Fabry Nephropathy: Sustained Reduction of Proteinuria in Patients Receiving Enzyme Replacement Therapy with Agalsidase-β. Journal of the American Society of Nephrology, 18, 2609-2617. https://doi.org/10.1681/ASN.2006121400
|
[85]
|
Ortiz, A., Oliveira, J.P., Wanner, C., Brenner, B.M., Waldek, S. and Warnock, D.G. (2008) Recommendations and Guidelines for the Diagnosis and Treatment of Fabry Nephropathy in Adults. Nature Clinical Practice Nephrology, 4, 327-336. https://doi.org/10.1038/ncpneph0806
|
[86]
|
Battaglia, Y., Bulighin, F., Zerbinati, L., Vitturi, N., Marchi, G. and Carraro, G. (2023) Dapaglifozin on Albuminuria in Chronic Kidney Disease Patients with FabrY Disease: The DEFY Study Design and Protocol. Journal of Clinical Medicine, 12, Article 3689. https://doi.org/10.3390/jcm12113689
|
[87]
|
Linhart, A., Germain, D.P., Olivotto, I., Akhtar, M.M., Anastasakis, A., Hughes, D., et al. (2020) An Expert Consensus Document on the Management of Cardiovascular Manifestations of Fabry Disease. European Journal of Heart Failure, 22, 1076-1096. https://doi.org/10.1002/ejhf.1960
|
[88]
|
Lee, C.L., Lin, S.P., Niu, D.M. and Lin, H.Y. (2022) Fabry Disease and the Effectiveness of Enzyme Replacement Therapy (ERT) in Left Ventricular Hypertrophy (LVH) Improvement: A Review and Meta-Analysis. International Journal of Medical Sciences, 19, 126-131. https://doi.org/10.7150/ijms.66448
|
[89]
|
Kampmann, C., Linhart, A., Baehner, F., Palecek, T., Wiethoff, C.M., Miebach, E., et al. (2008) Onset and Progression of the Anderson-Fabry Disease Related Cardiomyopathy. International Journal of Cardiology, 130, 367-373. https://doi.org/10.1016/j.ijcard.2008.03.007
|
[90]
|
Hughes, D.A., Nicholls, K., Shankar, S.P., Sunder-Plassmann, G., Koeller, D., Nedd, K., et al. (2017) Oral Pharmacological Chaperone Migalastat Compared with Enzyme Replacement Therapy in Fabry Disease: 18-Month Results from the Randomised Phase III ATTRACT Study. Journal of Medical Genetics, 54, 288-296.
|
[91]
|
Knoers, N., Antignac, C., Bergmann, C., Dahan, K., Giglio, S., Heidet, L., et al. (2022) Genetic Testing in the Diagnosis of Chronic Kidney Disease: Recommendations for Clinical Practice. Nephrology Dialysis Transplantation, 37, 239-254. https://doi.org/10.1093/ndt/gfab218
|
[92]
|
Rombach, S.M., Hollak, C.E., Linthorst, G.E. and Dijkgraaf, M.G. (2013) Cost-Effectiveness of Enzyme Replacement Therapy for Fabry Disease. Orphanet Journal of Rare Diseases, 8, Article No. 29. https://doi.org/10.1186/1750-1172-8-29
|
[93]
|
Moreno-Martinez, D., Aguiar, P., Auray-Blais, C., Beck, M., Bichet, D.G., Burlina, A., et al. (2021) Standardising Clinical Outcomes Measures for Adult Clinical Trials in Fabry Disease: A Global Delphi Consensus. Molecular Genetics and Metabolism, 132, 234-243. https://doi.org/10.1016/j.ymgme.2021.02.001
|
[94]
|
Hollak, C.E.M., Biegstraaten, M., Levi, M. and Hagendijk, R. (2015) Post-Authorisation Assessment of Orphan Drugs. The Lancet, 386, 1940-1941. https://doi.org/10.1016/S0140-6736(15)00827-2
|
[95]
|
Hollak, C.E.M., Sirrs, S., Van den Berg, S., Van der Wel, V., Langeveld, M., Dekker, H., et al. (2020) Registries for Orphan Drugs: Generating Evidence or Marketing Tools? Orphanet Journal of Rare Diseases, 15, Article No. 235. https://doi.org/10.1186/s13023-020-01519-0
|